Jan 22, 2024 7:00am EST ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
Nov 20, 2023 7:00am EST ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
Nov 14, 2023 4:30pm EST ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
Sep 06, 2023 12:18pm EDT ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference